Cargando…

Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented effects on reducing hospitalization for heart failure and cardiovascular mortality, although the effect on atrial fibrillation (AF) has not been comprehensively investigated. Therefore, we performed a meta-analysis to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Ru-Jie, Wang, Yue, Tang, Jun-Nan, Duan, Jie-Ying, Yuan, Ming-Yue, Zhang, Jin-Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Journal of Cardiovascular Pharmacology 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895972/ https://www.ncbi.nlm.nih.gov/pubmed/34813574 http://dx.doi.org/10.1097/FJC.0000000000001183

Ejemplares similares

SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
por: Li, Wen-jie, et al.
Publicado: (2020)

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis
por: Zhou, Zien, et al.
Publicado: (2021)

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
por: Li, Jiang, et al.
Publicado: (2023)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

CHADS(2) and CHA(2)DS(2)-VASc Scores Predict the Risk of Ischemic Stroke Outcome in Patients with Interatrial Block without Atrial Fibrillation
por: Wu, Jin-Tao, et al.
Publicado: (2017)

The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis
por: Wang, Miaomiao, et al.
Publicado: (2022)

Implications of SGLT Inhibition on Redox Signalling in Atrial Fibrillation
por: Bode, David, et al.
Publicado: (2021)

Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
por: Tsai, Wen-Hsuan, et al.
Publicado: (2021)

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
por: Li, Lu-Feng, et al.
Publicado: (2021)

Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
por: Gao, Yue-Ming, et al.
Publicado: (2022)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
por: Chang, Sheng‐Nan, et al.
Publicado: (2023)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
por: Li, Chun Xing, et al.
Publicado: (2023)

Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease
por: Zhang, Yaofu, et al.
Publicado: (2022)

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
por: Lu, Yan-Ting, et al.
Publicado: (2018)

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
por: Chua, Marvin Wei Jie
Publicado: (2021)

Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor
por: Monnerat, Sophie, et al.
Publicado: (2023)

Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
por: Zhou, Peipei, et al.
Publicado: (2023)

Atrial Fibrillation With and Without Cardiovascular Risk Factors and Stroke Mortality
por: Sairenchi, Toshimi, et al.
Publicado: (2021)

Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation
por: Vinding, Naja E., et al.
Publicado: (2022)

Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
por: Jiang, Kai, et al.
Publicado: (2021)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Neuroprotective Effect of SGLT2 Inhibitors
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Determinants of Left Atrial Appendage Volume in Stroke Patients without Chronic Atrial Fibrillation
por: Taina, Mikko, et al.
Publicado: (2014)

SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
por: Lin, Chu, et al.
Publicado: (2021)

Endocardial Changes in Nonvalvular Atrial Fibrillation Without Atrial Thrombus—Thrombomodulin and Tissue Factor Pathway Inhibitor
por: An, Kang, et al.
Publicado: (2018)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus
por: Lee, Kyuhyun, et al.
Publicado: (2023)

Correction to: Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation
Publicado: (2022)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
por: Ul Amin, Noor, et al.
Publicado: (2022)

Left Atrial Appendage Morphology in Patients with Suspected Cardiogenic Stroke without Known Atrial Fibrillation
por: Korhonen, Miika, et al.
Publicado: (2015)

Characteristics of Atrial Fibrillation Patients Suffering Esophageal Injury Caused by Ablation for Atrial Fibrillation
por: Zhang, Pei, et al.
Publicado: (2020)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e9b04gfo8i9ljjm3mdqv4cvuk5